Outcomes of melphalan 140 mg/m 2 followed by autologous stem cell transplantation in multiple myeloma patients with co‐morbidities: Single‐centre experience
eJHaem · 2024-10 · 5 (5) · 1102-1106
DOI: 10.1002/jha2.977 ↗Kurz gefasst
Fachartikel in der Zeitschrift eJHaem, online erschienen am 19.08.2024. Verfasst von Dario Melotti und 14 weiteren Autor:innen. Beteiligte Einrichtung: Haematology University College Hospital London UK. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 11 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
High‐dose melphalan followed by stem cell rescue is the standard consolidative therapy for transplant‐eligible patients with multiple myeloma (MM) in the United Kingdom. A melphalan dose of 200 mg/m 2 (Mel200) is considered the “gold standard” for autologous stem cell transplant (ASCT) conditioning for fit patients ≤70 years old; however, with a peak diagnosis incidence at 80–89 years old in the UK dose adjustments will be inevitable to limit toxicities. In this single‐centre UK‐based retrospective analysis, data was collected from patients with plasma cell dyscrasias who underwent a first reduced‐intensity, Mel140, ASCT from 2006 to 2019, a total of 81 patients. We found that the procedure was overall safe with seven (9%) of patients requiring ITU admission and a single transplant‐related death within the initial autograft admission. The progression‐free survival (PFS) and overall survival were comparable with those previously reported in the literature with median PFS for our cohort of 31 months. Univariate analysis of our data showed an inferior PFS for patients aged ≥70 years. In conclusion, although this is a retrospective analysis, it demonstrates that dose‐reduced melphalan conditioning is safe and effective in patients deemed unfit for standard‐intensity conditioning.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Haematology University College Hospital London UK.
- Department of Haematology University College London Hospitals NHS Foundation Trust London UK.
- Clinical Haematology Imperial College Healthcare NHS Trust London UK.
- CRUK and UCL Cancer Trials Centre University College London London UK.
- Haematology Bristol Haematology and Oncology Centre Bristol UK.
- Haematology University College London Hospitals NHS Foundation Trust London UK.
ORCID-Profile: Dario Melotti, Samir Asher, George Nesr, Marquita Camilleri, Ke Xu, Neil Rabin, Annabel McMillan
Zitieren
APA
Melotti, D., Asher, S., Troy-Barnes, E., Nesr, G., Wilson, W., Camilleri, M., Popat, R., Xu, K., Rabin, N., Sive, J., Papanikolaou, X., Lee, L., McMillan, A., Yong, K., & Kyriakou, C. (2024). Outcomes of melphalan 140 mg/m 2 followed by autologous stem cell transplantation in multiple myeloma patients with co‐morbidities: Single‐centre experience. eJHaem, 5(5), 1102-1106. https://doi.org/10.1002/jha2.977
Vancouver
Melotti D, Asher S, Troy-Barnes E, Nesr G, Wilson W, Camilleri M, et al. Outcomes of melphalan 140 mg/m 2 followed by autologous stem cell transplantation in multiple myeloma patients with co‐morbidities: Single‐centre experience. eJHaem. 2024;5(5):1102-1106. doi:10.1002/jha2.977
BibTeX
@article{Melotti2024,
author = {Melotti, Dario and Asher, Samir and Troy-Barnes, Ethan and Nesr, George and Wilson, William and Camilleri, Marquita and Popat, Rakesh and Xu, Ke and Rabin, Neil and Sive, Jonathan and Papanikolaou, Xenofon and Lee, Lydia and McMillan, Annabel and Yong, Kwee and Kyriakou, Chara},
title = {Outcomes of melphalan 140 mg/m 2 followed by autologous stem cell transplantation in multiple myeloma patients with co‐morbidities: Single‐centre experience},
journal = {eJHaem},
year = {2024},
volume = {5},
number = {5},
pages = {1102--1106},
doi = {10.1002/jha2.977}
}
EUVIMED